Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

500 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-09-11

Study Completion Date

2021-07-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a phase III clinical trial to evaluate efficacy, reactogenicity and safety of the vaccine Ad5-nCoV compared with placebo in volunteers at the age from 18 to 85 years，with the randomized, double-blind design

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Immunogenicity, Efficacy and Safety Trial of the Convacell Vaccine in Healthy Volunteers Aged 18 Years and Older

NCT05726084

COVID-19 Coronavirus Infections Respiratory Tract Infections +1 more

UNKNOWN PHASE2/PHASE3

Study of the Safety, Reactogenicity and Immunogenicity of "EpiVacCorona" Vaccine for the Prevention of COVID-19

NCT04527575

Covid19

COMPLETED PHASE1/PHASE2

Clinical Study of the Safety and Immunogenicity of a Recombinant Viral Vector AAV5 (Adeno-Associated Virus Type 5 )-RBD (Receptor Binding Domain)-S Vaccine for the Prevention of Coronavirus Infection (COVID-19)

NCT05037188

Coronavirus Infection COVID-19

TERMINATED PHASE1/PHASE2

Study of the Immunogenicity, Safety and Tolerability of the Convacell Vaccine.

NCT05156723

COVID-19 Immunologic Factors Coronavirus Infections +1 more

COMPLETED PHASE1/PHASE2

Study of the Tolerability, Safety, Immunogenicity and Preventive Efficacy of the EpiVacCorona Vaccine for the Prevention of COVID-19

NCT04780035

COVID-19

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A total of 500 healthy adult volunteers at the age from 18 to 85 years will be randomized into two treatment (vaccination) groups in ratio 3:1 by double-blind design.

Volunteers in group 1 (n=375) will be administered a single dose of the vaccine Ad5-nCoV (5E10vp).

Volunteers in group 2 (n=125): will be administered a single dose of placebo. Vaccine Ad5-nCoV or placebo will be administered intramuscularly into the deltoid muscle of the arm at a single dose of 0.5 mL (1 prefilled syringe).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ad5-nCoV single dose

375 subjects, Ad5-nCoV containing 5E10 vp, single dose

Group Type EXPERIMENTAL

Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

Intervention Type BIOLOGICAL

Intramuscular administration

Placebo single dose

125 subjects, Placebo containing 0 vp, single dose

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type BIOLOGICAL

Intramuscular administration

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

Intramuscular administration

Intervention Type BIOLOGICAL

Placebo

Intramuscular administration

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Presence of signed and dated Informed Consent of volunteer for participation in this study.
2. Men and women at the age of 18-85 years.
3. Bodyweight index 18.5-30.0 kg/m2.
4. The negative result of the test, performed by using PCR, for the presence of SARS-CoV-2 RNA at the stage of screening.
5. Negative result for anti-SARS-CoV-2 IgM and IgG antibodies at the stage of screening.
6. No history of the diagnosis COVID-19.
7. Absence of close contacts with individuals, suspicious for infection SARS-CoV-2, or individuals, in whom the diagnosis COVID-19 was confirmed in laboratory within the last 14 days.
8. Absence of signs of respiratory infection within the last 14 days.
9. Negative results of human immunodeficiency virus (HIV), syphilis, hepatitis B and hepatitis C tests.
10. According to historical data and results of screening examination, a volunteer has no diseases and/or conditions, which in view of Investigator, may influence the safety of volunteer participation and evaluation of study results.
11. Volunteer consent for using safe contraceptive methods through all the study.

Exclusion Criteria

1. Positive history of allergy, drug intolerance, including increased sensibility to any of components of the test drug product, as well as the history of serious adverse events in the administration of vaccines (such as allergic reactions, respiratory disturbance, angioedema, stomach pain).
2. Axillary body temperature ≥37.1 °C at the time of screening/randomization.
3. Systolic blood pressure more than 139 mm Hg or less than 100 mm Hg and/or diastolic blood pressure more than 90 mm Hg or less than 60 mm Hg.
4. Clinical significant abnormal laboratory and/or instrumental parameters at screening examination.
5. Acute infectious diseases less than 4 weeks ahead of conduction of screening procedures.
6. Acute and acute course of chronic diseases of GIT, liver, kidneys, cardiovascular, respiratory, nervous and endocrine systems.
7. History of blood and hematopoietic organ diseases.
8. History of diabetes mellitus.
9. History of epilepsy, epileptic syndrome, seizures.
10. History of congenital and acquired immunodeficiency, HIV-infection, lymphoma, leukaemia, systemic lupus erythematosus, juvenile rheumatoid arthritis or other autoimmune diseases.
11. History malignancies.
12. Using immunotropic preparations (immunomodulators, immunostimulators, immunodepressants), antiallergic, cytotoxic preparations for more than 10 sequential days within the last 3 months (except for inhalant and local using glucocorticoids \[GCS\] or using specified preparations less than 4 weeks ahead of the screening.
13. Using immunoglobulin preparations or blood transfusion less than 3 months ahead of the screening.
14. Using antipyretics (including non-steroidal anti-inflammatory agents and anilides) within 24 hours ahead of randomization.
15. Blood donation or loss (≥450 mL of blood or plasma) less than 3 months ahead of the screening.
16. Vaccination within 6 mon. ahead of screening or reluctance to refuse from the administration of any other vaccine during the study.
17. Anamnestic data/data on alcoholism, narcomania, drug abuse, mental illnesses.
18. Major surgery planned within the nearest 6 months or underwent within the last 6 months ahead of the screening.
19. Carrying out of body piercing procedures, an appendix of tattoo less than 1 month ahead of conduction of screening procedures and through all the study.
20. Pregnancy or breast-feeding period.
21. Participation in another clinical study within 3 months ahead of the screening.
22. Psychic, physical and other reasons, not allowing a volunteer to adhere to conditions and procedures of Study Protocol.
23. Volunteers, who are Clinical Site staff.
24. Other reasons, not allowing the volunteer to take part in this study in view of the study physician.

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes